MBBS, FACEM, FCICM, PhD
Matt is a senior consultant in Intensive Care Medicine and Emergency Medicine who has worked in Geelong for over 10 years. He has provided a VMO service at St John of God Hospital, consults at the Geelong Hospital Emergency Department and maintains a research program at the Royal Adelaide Hospital ICU.
Matt has a particular interest in pre-clinical research and has completed a PhD thesis describing the thyroid hormone changes in critical illness. Otherwise it is music, horses, Essendon Football Club or running around 5 children that occupies his time.
Head of Research
Matt has a particular interest in pre-clinical research and has completed a PhD thesis describing the thyroid hormone changes in critical illness. Otherwise it is music, horses, Essendon Football Club or running around 5 children that occupies his time.
Latest news:
-
Tuesday, June 28, 2022 - 12:15
JAMA NITRIC Trial: Among 1371 infants undergoing congenital heart surgery requiring CPB, delivery of nitric oxide into the CPB did not increase ventilator-free survival censored at 28 days. No benefit in secondary outcomes or subgroups was observed, including subgroup of children less than 6-weeks.
Tuesday, June 28, 2022 - 10:51JAMA Viewpoint: Surrogate decision-making is difficult. Respecting the authenticity and sovereignty of advance care directives,. Juggling these with the emotional burden of conflicting family morals during substituted judgement. Wendler expertly provides us the hierarchy of values for autonomy in treatment decision-making - non-intrusion, sovereignty, authenticity, best interest, moral standing - and urges us to consider them in our care.
Thursday, June 23, 2022 - 14:36NEJM LOVIT IV vitamin C in critically ill patients with sepsis requiring vasopressors associated increased risk of death or organ dysfunction at D28 vs placebo. Secondary outcomes including biomarkers identify no mechanism. Only RCT reporting benefit is CITRIS-ALI (lung injury), with no benefit septic shock (LOVIT, VITAMINS, ACTS, VICTAS). Ongoing COVID-19 and ARDS trials may further elucidate.
Thursday, June 23, 2022 - 13:01NEJM CLASSIC Trial: No difference 90-day mortality or serious adverse events among patients who received restricted fluid therapy vs standard therapy. The two groups had similar survival durations without life support and after hospital discharge at 90 days
Thursday, June 23, 2022 - 11:57JAMA PREPARE II Among critically ill adults undergoing tracheal intubation, administration of a fluid bolus did not significantly decrease the incidence of cardiovascular collapse